Quick answers
- What is Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate used for?
- The FDA-approved label (Normosol-M and Dextrose, ICU Medical Inc., October 24, 2025) says: “Normosol-M and 5% Dextrose Injection (Multiple Electrolytes and 5% Dextrose Injection Type 1, USP) is indicated for parenteral maintenance of routine daily fluid and electrolyte requirements with minimal carbohydrate calories from dextrose. Magnesium in the formula may help to prevent iatrogenic magnesium deficiency in patients receiving prolonged parenteral therapy.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate?
- The “Adverse Reactions” section of the FDA label (Normosol-M and Dextrose, ICU Medical Inc., October 24, 2025) begins: “Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate?
- 1 company lists prescription products of Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate in the FDA NDC Directory, including ICU Medical Inc.
What Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Normosol-M and 5% Dextrose Injection (Multiple Electrolytes and 5% Dextrose Injection Type 1, USP) is indicated for parenteral maintenance of routine daily fluid and electrolyte requirements with minimal carbohydrate calories from dextrose. Magnesium in the formula may help to prevent iatrogenic magnesium deficiency in patients receiving prolonged parenteral therapy.
— FDA label: Normosol-M and Dextrose, ICU Medical Inc., effective October 24, 2025. Read the full label on DailyMed →
Label quoted: the one for the most common form (injection, solution, intravenous), Normosol-M and Dextrose, ICU Medical Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
— FDA label: Normosol-M and Dextrose, ICU Medical Inc., effective October 24, 2025. Read the full label on DailyMed →
Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Normosol-M and 5% Dextrose Injection is administered by intravenous infusion. The dose is dependent upon the age, weight and clinical condition of the patient. A daily total amount of 1500 mL/M 2 of body surface will meet the usual adult daily requirements for water and principal electrolytes in patients unable to take anything by mouth. The usual daily maintenance amount for an average adult (70 kg and 1.8 square meters of body surface) is approximately three liters.
Read more of this section
As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Drug Interactions Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. To avoid precipitation of calcium salts that may occur when certain drugs are added, Normosol-M and 5% Dextrose Injection does not contain calcium. Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS. INSTRUCTIONS FOR USE To Open Tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. If supplemental medication is desired, follow directions below before preparing for administration. To Add Medication Prepare additive port. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication. The additive port may be protected by covering with an additive cap. Mix container contents thoroughly. To Administer Attach administration set per manufacturer’s instructions. Regulate rate of administration per institutional policy. WARNING: Do not use flexible container in series connections.
— FDA label: Normosol-M and Dextrose, ICU Medical Inc., effective October 24, 2025. Read the full label on DailyMed →
Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Category C. Animal reproduction studies have not been conducted with Normosol-M and 5% Dextrose Injection. It is also not known whether this solution can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This solution should be given to a pregnant woman only if clearly needed.
— FDA label: Normosol-M and Dextrose, ICU Medical Inc., effective October 24, 2025. Read the full label on DailyMed →
Dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS, PRECAUTIONS and ADVERSE REACTIONS.
— FDA label: Normosol-M and Dextrose, ICU Medical Inc., effective October 24, 2025. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Injection, solution |
|---|---|
| Route | Intravenous |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Normosol-M and Dextrose |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- ICU Medical Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA017610 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER | Otsuka Icu Medcl | August 13, 1975 | 93, latest September 8, 2014 2014: Manufacturing (CMC) · 1999: Labeling · 1998: Manufacturing (CMC) |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 801005, 801009 |
|---|---|
| SPL set ID of the quoted label | aba60c84-94d9-46d0-bdbb-25e0c4e8cc41 |
| FDA labels (SPL) | 1 |
| FDA applications | NDA017610 |
| Active ingredients (FDA) | DEXTROSE MONOHYDRATE / MAGNESIUM ACETATE / POTASSIUM ACETATE / SODIUM CHLORIDE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- ICU Medical Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Normosol-M and Dextrose, ICU Medical Inc., effective October 24, 2025; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →